tiprankstipranks
Trending News
More News >
Kiora Pharmaceuticals (KPRX)
NASDAQ:KPRX
Advertisement

Kiora Pharmaceuticals (KPRX) AI Stock Analysis

Compare
475 Followers

Top Page

KPRX

Kiora Pharmaceuticals

(NASDAQ:KPRX)

Select Model
Select Model
Select Model
Neutral 56 (OpenAI - 4o)
Rating:56Neutral
Price Target:
Kiora Pharmaceuticals shows strong financial health with solid revenue growth and minimal debt, contributing positively to its stock score. However, weak technical indicators suggest bearish market sentiment, partially offsetting the financial strengths. The attractive valuation with a low P/E ratio presents potential upside, particularly if technical conditions improve.
Positive Factors
Revenue Growth
The substantial revenue growth in 2024 indicates a successful market penetration and product acceptance, positioning Kiora for continued expansion in the ophthalmic sector.
Financial Stability
Minimal leverage and a strong equity position provide Kiora with financial flexibility to invest in R&D and withstand market fluctuations, supporting long-term growth.
Profitability
A high gross profit margin reflects efficient cost management and strong pricing power, enhancing Kiora's ability to reinvest in growth initiatives and improve profitability.
Negative Factors
Cash Flow Management
Limited cash flow leverage could restrict Kiora's ability to fund new projects or navigate financial challenges, potentially impacting long-term operational flexibility.
Net Profit Margin
While profitable, the net profit margin suggests room for improving cost controls, which is crucial for sustaining profitability as the company scales operations.
Cash Flow Efficiency
Improving cash flow efficiency is essential for Kiora to enhance liquidity, support strategic investments, and ensure long-term financial health.

Kiora Pharmaceuticals (KPRX) vs. SPDR S&P 500 ETF (SPY)

Kiora Pharmaceuticals Business Overview & Revenue Model

Company DescriptionKiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
How the Company Makes MoneyKiora Pharmaceuticals generates revenue primarily through the sale and licensing of its ophthalmic products and therapies. The company's revenue model includes direct sales to healthcare providers, partnerships with pharmaceutical companies for the co-development and distribution of its products, and potential milestone payments and royalties from licensing agreements. These partnerships and collaborations are crucial as they provide access to broader markets and additional resources for research and development. Kiora's focus on innovative treatments for eye disorders positions it to capture a niche market, potentially leading to substantial revenue growth as its products gain regulatory approval and market acceptance.

Kiora Pharmaceuticals Financial Statement Overview

Summary
Kiora Pharmaceuticals exhibits a positive trajectory with substantial revenue growth and improved profitability in 2024. The company maintains strong financial stability with minimal leverage and a solid equity position. However, cash flow metrics indicate room for improvement in operational efficiency and cash management. The overall financial health is promising, with potential risks mitigated by strong equity foundations.
Income Statement
45
Neutral
Kiora Pharmaceuticals showed significant revenue growth in 2024 with a total revenue of $16.02 million compared to zero in previous years, indicating a positive turnaround. The gross profit margin is 100% for 2024, suggesting effective cost management. However, the net profit margin stands at 48.2%, hinting at some cost controls needing improvement. The EBIT margin is at 16.4%, but the absence of EBITDA data limits further analysis.
Balance Sheet
60
Neutral
The balance sheet reveals a solid equity position with a debt-to-equity ratio of 0.002, indicating minimal leverage and strong financial stability. The return on equity is 30%, reflecting efficient use of equity to generate profits. The equity ratio is 70.6%, suggesting a healthy balance between debt and equity financing.
Cash Flow
55
Neutral
The company experienced positive free cash flow in 2024, a substantial improvement from previous years. The free cash flow to net income ratio is 1.11, indicating strong cash generation relative to profits. However, the operating cash flow to net income ratio of 1.11 suggests that cash generation from operations aligns closely with net income, which may limit further cash flow leverage.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.0016.02M0.000.000.0012.06K
Gross Profit-16.05M16.00M-4.03M-134.03K-227.27K-188.16K
EBITDA-9.48M5.75M-12.35M-10.69M-13.73M-6.65M
Net Income-11.98M3.59M-12.51M-13.58M-16.39M-6.86M
Balance Sheet
Total Assets31.95M36.48M13.71M18.68M18.06M15.30M
Cash, Cash Equivalents and Short-Term Investments20.67M26.79M2.45M5.96M7.85M1.19M
Total Debt430.41K57.17K106.89K105.78K209.41K574.40K
Total Liabilities9.82M10.72M7.60M7.27M5.55M5.57M
Stockholders Equity22.13M25.76M6.11M11.41M14.58M9.73M
Cash Flow
Free Cash Flow-7.83M8.55M-9.56M-10.43M-10.95M-7.45M
Operating Cash Flow-7.84M8.56M-9.56M-10.43M-10.89M-7.32M
Investing Cash Flow1.90M-22.66M0.006.38K-157.02K-244.44K
Financing Cash Flow265.36K15.50M5.97M8.62M17.58M5.00M

Kiora Pharmaceuticals Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price2.63
Price Trends
50DMA
2.69
Negative
100DMA
2.88
Negative
200DMA
3.11
Negative
Market Momentum
MACD
-0.03
Positive
RSI
48.34
Neutral
STOCH
38.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KPRX, the sentiment is Neutral. The current price of 2.63 is below the 20-day moving average (MA) of 2.65, below the 50-day MA of 2.69, and below the 200-day MA of 3.11, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 48.34 is Neutral, neither overbought nor oversold. The STOCH value of 38.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for KPRX.

Kiora Pharmaceuticals Risk Analysis

Kiora Pharmaceuticals disclosed 49 risk factors in its most recent earnings report. Kiora Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Kiora Pharmaceuticals Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
56
Neutral
$8.96M4.67-43.39%-100.00%49.47%
48
Neutral
$10.64M-0.22-805.89%-57.69%63.76%
45
Neutral
$9.43M-1.14-54.54%-48.61%32.18%
39
Underperform
$6.42M-0.3853.79%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
KPRX
Kiora Pharmaceuticals
2.63
-0.94
-26.33%
GNPX
Genprex
0.17
-0.18
-51.43%
DWTX
Dogwood Therapeutics
7.91
4.01
102.82%
SNSE
Sensei Biotherapeutics
9.55
-0.31
-3.14%
RNAZ
TransCode Therapeutics
10.64
-437.59
-97.63%
AEON
AEON Biopharma
0.82
-72.62
-98.88%

Kiora Pharmaceuticals Corporate Events

Product-Related AnnouncementsRegulatory Filings and Compliance
Kiora Pharmaceuticals Gains Approval for Phase 2 Trial
Positive
Oct 29, 2024

Kiora Pharmaceuticals has received regulatory approval to begin a Phase 2 clinical trial of KIO-301 for treating retinitis pigmentosa, aiming to restore vision in patients with severe vision loss. The ABACUS-2 trial will assess the drug’s safety and efficacy across multiple centers in Australia, utilizing a unique photoswitch mechanism that could work for various gene mutations associated with retinal diseases. This innovative approach, supported by Théa Open Innovation, offers hope for a breakthrough in treating inherited retinal conditions.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 20, 2025